Chemomab Therapeutics (CMMB) Net Cash Flow (QoQ) (2018 - 2023)
Chemomab Therapeutics (CMMB) Net Cash Flow (QoQ) (2018 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 111.40% |
| Sep 30, 2023 | 88.18% |
| Jun 30, 2023 | -243.33% |
| Mar 31, 2023 | 160.84% |
| Dec 31, 2022 | 223.78% |
| Sep 30, 2022 | 121.71% |
| Jun 30, 2022 | -197.37% |
| Mar 31, 2022 | 94.11% |
| Dec 31, 2021 | -194.77% |
| Sep 30, 2021 | 40.13% |
| Jun 30, 2021 | -127.49% |
| Mar 31, 2021 | 4,773.77% |
| Dec 31, 2020 | -177.16% |
| Sep 30, 2020 | -116.15% |
| Jun 30, 2020 | 256.22% |
| Mar 31, 2020 | 74.87% |
| Dec 31, 2019 | -50.53% |
| Sep 30, 2019 | 26.65% |
| Jun 30, 2019 | -120.83% |
| Mar 31, 2019 | 702.00% |